A carregar...
Dawn of Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma
Two Chimeric Antigen Receptor (CAR) T cell therapies are now approved for the treatment of relapsed and refractory large cell lymphomas, with many others under development. The dawn of CAR T cell therapy in non-Hodgkin Lymphoma (NHL) has been characterized by rapid progress and high response rates,...
Na minha lista:
| Publicado no: | Adv Cell Gene Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7544150/ https://ncbi.nlm.nih.gov/pubmed/33043278 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acg2.23 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|